Gabapentin
Product Images NDC 68788-7049

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 01)

This is a dosage table for Gabapentin based on renal function. The table provides the dosage range for patients with different levels of creatinine clearance, measured in mL/min. The dosages are divided into Total Daily Dose and Post-Hemodialysis Supplemental Dose. The table also includes the dosing frequency acronyms TID, BID, and QD, which respectively stand for three times a day, two times a day, and a single daily dose. Patients with creatinine clearance <15 mL/min should receive a reduced daily dose. Patients on hemodialysis should receive maintenance doses based on creatinine clearance estimates and a supplemental post-hemodialysis dose.*

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 02)

This text seems to be a formula or calculation for estimating creatinine clearance (CLCy) based on the weight of the patient in kilograms and their serum creatinine level in milligrams per deciliter. The formula includes a coefficient of 0.85 for female patients. However, the text is incomplete and it is difficult to provide more context or a specific interpretation without additional information.*

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 03)

This is a table containing information about the risk of antiepileptic drugs. The table lists indications such as epilepsy, psychiatric disorders, and others, along with the number of events per 1000 patients. The data is broken down into two categories: placebo patients and drug patients. A relative risk analysis is also given, as well as a risk difference analysis, both of which are based on the incidence of events in drug patients compared to placebo patients. No additional information is available.*

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 04)

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 05)

The text is a chart showing the mean pain score during a dose titration period and a fixed dose period of 8 weeks. The chart includes a placebo group and a group taking 3600 mg/day of Gabapentin. There is no further context or explanation provided.*

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 06)

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 07)

The text is a graph description showing the proportion of responders with more than 50% reduction in pain score in controlled postherpetic neuralgia (PHN) studies. The graph shows two studies, Study 1 and Study 2, with Study 2 having a higher response rate of 34%. The numbers at the end appear to be dosages or treatments used in the studies.*

FDA Label Image

Image (54f184de Ba3e 4db8 Ae88 B4c06263df79 08)

FDA Label Image

Gabapentin Capsules, Usp 600mg (54f184de Ba3e 4db8 Ae88 B4c06263df79 09)

Description: Gabapentin Tab 600mg (CV) is a medication manufactured by Cipla USA Inc. It is a generic product for Neurontin and each tablet contains 600mg Gabapentin. The package size, expiration date, and batch number are provided on the label.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.